Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Decision Diagnostics Corp. (DECN)
Westlake Village, CA, US
Decision Diagnostics Corp. (DECN), founded in 2000 and based in Westlake Village, California, specializes in developing electronic medical record (EMR) technologies primarily optimized for smartphones. The company provides a wide array of offerings, including both regulated and unregulated diagnostic solutions, as well as home-use testing products for individuals managing chronic illnesses. They also facilitate direct-to-patient logistics for diabetes programs and concentrate on creating mobile-centric e-health products and associated technological innovations. A key part of their product line involves glucose monitoring. This includes the GenUltimate! glucose test strips, classified as a Class II medical device for personal at-home human use. For animal health, they manufacture PetSure! glucose test strips, designed to measure glucose levels in dogs and cats and compatible with legacy Zoetis AlphaTrak glucometers. Additionally, they offer the proprietary GenUltimate! 4Pets Glucose system, which combines the GenUltimate! 4Pets strip with the Avantage meter, enabling glucose testing for canine, feline, and equine patients. Further glucose strip options include GenUltimate! Sure and GenUltimate! Precis. Beyond product development, Decision Diagnostics actively acquires and maintains a portfolio of intellectual property, spanning patents, trademarks, and specialized manufacturing equipment. Their software solutions include MD@Hand, a comprehensive management system for both inpatient and outpatient care; Practice Probe, a data mining utility designed to extract information from physician practice management systems; and ResidenceWare, a residential management system that streamlines communication between commercial or residential real estate managers and their tenants through networked applications. Ultimately, their EMR innovations provide crucial tools for physicians directly at the point of patient care. The company was originally known as InstaCare Corp. before officially changing its name to Decision Diagnostics Corp. in November 2011.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -33.77% | +9,900.00% | +0.00% | +9,900.00% | +0.00% | +0.00% | -99.33% | -99.97% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-16.8% Q3'21: -0.4% (vs Q3'20)
-
EPS growth Medical - Pharmaceuticals: +20.2%-428.9% Q3'21: +89.7% (vs Q3'20)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-1,466.9% Q3'21: -12.0% (vs Q3'20)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-121.6% Q3'21: -94.6% (vs Q3'20)
-
ROIC Medical - Pharmaceuticals: +6.1%-83.3% Q3'21: -66.0% (vs Q3'20)
-
Share dilution Medical - Pharmaceuticals: +0.0%+77.3% Q3'21: +17.4% (vs Q3'20)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-1.22× Q3'21: -1.65× (vs Q3'20)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 03-0021366 | 29.15M | 9.99% | — | 29.15M | — | 29.15M | PN | California | 2005-02-25 | ↗ |
| 2 | 300021359 | 29.15M | 9.99% | — | 29.15M | — | 29.15M | IA | California | 2005-02-25 | ↗ |
| 3 | David F. Firestone | 29.15M | 9.99% | — | 29.15M | — | 29.15M | IA | USA | 2005-02-25 | ↗ |
| 4 | Monarch Pointe Fund, Ltd. | 29.15M | 9.99% | — | 29.15M | — | 29.15M | PN | British Virgin Islands | 2005-02-25 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Keith Berman | Chief Executive Officer, Chief Financial Officer, Secretary & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DECN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
